Novartis Total Other Income Expense Net vs Operating Income Analysis

NVS Stock

USD 109.05 0.13 0.12%

Novartis financial indicator trend analysis is infinitely more than just investigating Novartis AG ADR recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novartis AG ADR is a good investment. Please check the relationship between Novartis Total Other Income Expense Net and its Operating Income accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

Total Other Income Expense Net vs Operating Income

Total Other Income Expense Net vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novartis AG ADR Total Other Income Expense Net account and Operating Income. At this time, the significance of the direction appears to have pay attention.

The correlation between Novartis' Total Other Income Expense Net and Operating Income is -0.89. Overlapping area represents the amount of variation of Total Other Income Expense Net that can explain the historical movement of Operating Income in the same time period over historical financial statements of Novartis AG ADR, assuming nothing else is changed. The correlation between historical values of Novartis' Total Other Income Expense Net and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Other Income Expense Net of Novartis AG ADR are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Total Other Income Expense Net i.e., Novartis' Total Other Income Expense Net and Operating Income go up and down completely randomly.

Correlation Coefficient

-0.89

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Total Other Income Expense Net

Operating Income

Operating Income is the amount of profit realized from Novartis AG ADR operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Novartis AG ADR is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from Novartis' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novartis AG ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novartis AG ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

At this time, Novartis' Discontinued Operations is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 0.05 in 2025, whereas Tax Provision is likely to drop slightly above 1.7 B in 2025.

	2022	2023	2024	2025 (projected)
Gross Profit	36.3B	34.2B	38.9B	32.6B
Total Revenue	51.8B	46.7B	51.7B	46.5B

Gross Profit Total Revenue

Novartis fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Capital Stock
Total Assets		0.64	0.77	0.73	0.91	0.78	0.52	0.66	0.92	0.92	0.24	0.97	-0.32	0.11	0.74	-0.06	-0.17	-0.01	0.88	0.78	0.04	-0.54	0.86	0.28	0.41	0.02
Short Long Term Debt Total	0.64		0.8	0.88	0.28	0.09	0.15	0.9	0.39	0.59	0.6	0.56	0.31	0.42	0.44	-0.49	-0.52	0.14	0.89	0.54	-0.04	0.12	0.92	0.29	0.48	-0.46
Other Current Liab	0.77	0.8		0.96	0.51	0.38	0.19	0.67	0.56	0.85	0.58	0.64	-0.1	0.47	0.47	-0.33	-0.41	0.21	0.81	0.66	0.27	-0.08	0.91	0.31	0.7	-0.29
Total Current Liabilities	0.73	0.88	0.96		0.41	0.28	0.09	0.76	0.48	0.79	0.6	0.61	0.01	0.46	0.46	-0.42	-0.49	0.19	0.82	0.66	0.23	0.05	0.93	0.37	0.65	-0.4
Total Stockholder Equity	0.91	0.28	0.51	0.41		0.91	0.63	0.35	0.97	0.81	0.0	0.91	-0.52	-0.06	0.7	0.17	0.06	-0.06	0.63	0.68	0.0	-0.75	0.57	0.19	0.25	0.25
Property Plant And Equipment Net	0.78	0.09	0.38	0.28	0.91		0.45	0.21	0.84	0.74	-0.18	0.84	-0.65	-0.33	0.68	0.32	0.21	-0.29	0.5	0.62	0.06	-0.83	0.43	0.21	0.03	0.41
Current Deferred Revenue	0.52	0.15	0.19	0.09	0.63	0.45		0.1	0.69	0.36	0.14	0.55	-0.36	-0.12	0.22	0.08	0.04	-0.26	0.33	0.13	-0.22	-0.59	0.25	0.16	0.04	0.12
Net Debt	0.66	0.9	0.67	0.76	0.35	0.21	0.1		0.43	0.58	0.19	0.65	0.23	0.17	0.55	-0.37	-0.4	0.11	0.88	0.6	-0.04	0.04	0.87	0.18	0.22	-0.31
Retained Earnings	0.92	0.39	0.56	0.48	0.97	0.84	0.69	0.43		0.82	0.09	0.92	-0.43	-0.01	0.72	0.05	-0.05	-0.06	0.68	0.65	-0.08	-0.71	0.63	0.29	0.28	0.13
Accounts Payable	0.92	0.59	0.85	0.79	0.81	0.74	0.36	0.58	0.82		0.26	0.88	-0.43	0.11	0.67	-0.09	-0.24	-0.02	0.79	0.76	0.23	-0.45	0.83	0.46	0.43	-0.06
Cash	0.24	0.6	0.58	0.6	0.0	-0.18	0.14	0.19	0.09	0.26		0.07	0.28	0.65	-0.02	-0.42	-0.42	0.11	0.37	0.11	0.0	0.21	0.48	0.34	0.69	-0.48
Non Current Assets Total	0.97	0.56	0.64	0.61	0.91	0.84	0.55	0.65	0.92	0.88	0.07		-0.38	-0.13	0.77	0.03	-0.08	-0.2	0.86	0.72	-0.03	-0.65	0.79	0.31	0.16	0.11
Non Currrent Assets Other	-0.32	0.31	-0.1	0.01	-0.52	-0.65	-0.36	0.23	-0.43	-0.43	0.28	-0.38		0.38	-0.02	-0.62	-0.55	0.22	-0.02	-0.27	-0.56	0.64	-0.01	-0.09	0.1	-0.63
Cash And Short Term Investments	0.11	0.42	0.47	0.46	-0.06	-0.33	-0.12	0.17	-0.01	0.11	0.65	-0.13	0.38		-0.15	-0.43	-0.39	0.81	0.16	0.23	0.22	0.52	0.29	-0.14	0.91	-0.45
Net Receivables	0.74	0.44	0.47	0.46	0.7	0.68	0.22	0.55	0.72	0.67	-0.02	0.77	-0.02	-0.15		-0.08	-0.24	-0.17	0.65	0.55	-0.43	-0.5	0.6	0.42	0.11	-0.02
Common Stock Total Equity	-0.06	-0.49	-0.33	-0.42	0.17	0.32	0.08	-0.37	0.05	-0.09	-0.42	0.03	-0.62	-0.43	-0.08		0.95	-0.12	-0.23	-0.03	0.27	-0.57	-0.32	-0.28	-0.33	0.97
Common Stock Shares Outstanding	-0.17	-0.52	-0.41	-0.49	0.06	0.21	0.04	-0.4	-0.05	-0.24	-0.42	-0.08	-0.55	-0.39	-0.24	0.95		-0.07	-0.31	-0.1	0.3	-0.49	-0.4	-0.45	-0.34	0.97
Short Term Investments	-0.01	0.14	0.21	0.19	-0.06	-0.29	-0.26	0.11	-0.06	-0.02	0.11	-0.2	0.22	0.81	-0.17	-0.12	-0.07		-0.03	0.25	0.35	0.47	0.06	-0.42	0.67	-0.11
Non Current Liabilities Total	0.88	0.89	0.81	0.82	0.63	0.5	0.33	0.88	0.68	0.79	0.37	0.86	-0.02	0.16	0.65	-0.23	-0.31	-0.03		0.68	-0.02	-0.28	0.97	0.27	0.35	-0.17
Inventory	0.78	0.54	0.66	0.66	0.68	0.62	0.13	0.6	0.65	0.76	0.11	0.72	-0.27	0.23	0.55	-0.03	-0.1	0.25	0.68		0.33	-0.25	0.7	0.1	0.46	0.02
Other Current Assets	0.04	-0.04	0.27	0.23	0.0	0.06	-0.22	-0.04	-0.08	0.23	0.0	-0.03	-0.56	0.22	-0.43	0.27	0.3	0.35	-0.02	0.33		0.09	0.08	-0.22	0.28	0.25
Other Stockholder Equity	-0.54	0.12	-0.08	0.05	-0.75	-0.83	-0.59	0.04	-0.71	-0.45	0.21	-0.65	0.64	0.52	-0.5	-0.57	-0.49	0.47	-0.28	-0.25	0.09		-0.15	-0.13	0.24	-0.64
Total Liab	0.86	0.92	0.91	0.93	0.57	0.43	0.25	0.87	0.63	0.83	0.48	0.79	-0.01	0.29	0.6	-0.32	-0.4	0.06	0.97	0.7	0.08	-0.15		0.33	0.49	-0.27
Property Plant And Equipment Gross	0.28	0.29	0.31	0.37	0.19	0.21	0.16	0.18	0.29	0.46	0.34	0.31	-0.09	-0.14	0.42	-0.28	-0.45	-0.42	0.27	0.1	-0.22	-0.13	0.33		0.01	-0.39
Total Current Assets	0.41	0.48	0.7	0.65	0.25	0.03	0.04	0.22	0.28	0.43	0.69	0.16	0.1	0.91	0.11	-0.33	-0.34	0.67	0.35	0.46	0.28	0.24	0.49	0.01		-0.33
Capital Stock	0.02	-0.46	-0.29	-0.4	0.25	0.41	0.12	-0.31	0.13	-0.06	-0.48	0.11	-0.63	-0.45	-0.02	0.97	0.97	-0.11	-0.17	0.02	0.25	-0.64	-0.27	-0.39	-0.33

Click cells to compare fundamentals

Novartis Account Relationship Matchups

Novartis fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	132.1B	131.8B	117.5B	99.9B	102.2B	103.5B
Short Long Term Debt Total	38.0B	31.1B	28.0B	26.3B	31.3B	19.2B
Other Current Liab	15.1B	15.5B	14.7B	12.6B	13.4B	11.2B
Total Current Liabilities	33.1B	30.2B	28.7B	26.4B	28.7B	22.4B
Total Stockholder Equity	56.6B	67.7B	59.3B	46.7B	44.0B	56.8B
Property Plant And Equipment Net	13.9B	13.1B	12.2B	10.9B	10.9B	13.4B
Current Deferred Revenue	114M	56M	123M	98M	127M	136.0M
Net Debt	28.4B	18.7B	20.4B	13.0B	19.8B	11.4B
Retained Earnings	57.2B	71.0B	63.5B	49.6B	57.1B	58.0B
Accounts Payable	5.4B	5.6B	5.1B	4.9B	4.6B	4.2B
Cash	9.7B	12.4B	7.5B	13.4B	11.5B	7.9B
Non Current Assets Total	102.4B	86.1B	80.5B	69.5B	72.5B	73.5B
Non Currrent Assets Other	892M	2.2B	1.1B	2.2B	4.5B	4.7B
Cash And Short Term Investments	11.6B	28.3B	18.9B	14.0B	13.4B	13.1B
Net Receivables	9.1B	8.8B	8.9B	8.1B	9.5B	8.9B
Common Stock Shares Outstanding	2.3B	2.3B	2.2B	2.1B	2.0B	1.9B
Short Term Investments	1.9B	15.9B	11.4B	569M	1.9B	1.8B
Liabilities And Stockholders Equity	132.1B	131.8B	117.5B	99.9B	102.2B	103.5B
Non Current Liabilities Total	42.3B	33.8B	29.4B	26.8B	29.4B	23.9B
Inventory	7.1B	6.7B	7.2B	5.9B	5.7B	6.0B
Other Current Assets	2.9B	2.8B	2.9B	2.0B	1.1B	1.0B
Other Stockholder Equity	(59.4B)	(53M)	(48M)	(92M)	(41M)	(55.7M)
Total Liab	75.4B	64.0B	58.0B	53.2B	58.1B	46.3B
Property Plant And Equipment Gross	13.9B	13.1B	12.2B	22.8B	22.0B	14.4B
Total Current Assets	29.7B	45.7B	36.9B	30.5B	29.7B	30.0B
Capital Stock	913M	901M	890M	825M	793M	762.7M
Short Term Debt	10.1B	6.6B	6.2B	6.3B	8.3B	6.4B
Common Stock	913M	901M	890M	825M	793M	762.7M
Accumulated Other Comprehensive Income	55.7B	66.8B	58.5B	(3.8B)	43.3B	50.3B
Intangible Assets	36.8B	34.2B	31.6B	26.9B	26.9B	22.7B
Other Liab	12.5B	14.4B	9.2B	7.6B	8.7B	8.5B
Other Assets	14.8B	14.7B	12.4B	4.8B	5.6B	10.1B
Long Term Debt	26.3B	22.9B	20.2B	18.4B	21.4B	13.3B
Good Will	30.0B	29.6B	29.3B	23.3B	24.8B	22.2B
Treasury Stock	(80M)	(53M)	(48M)	(41M)	(47.2M)	(49.5M)
Property Plant Equipment	13.7B	13.9B	13.1B	12.2B	14.0B	14.0B
Net Tangible Assets	5.6B	(5.5B)	9.4B	2.8B	2.5B	2.4B
Noncontrolling Interest In Consolidated Entity	68M	167M	81M	83M	95.5M	93.5M
Deferred Long Term Liab	5.4B	4.7B	5.5B	4.4B	5.1B	5.8B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Novartis Stock Analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC